Approval · Notice of Compliance 2922 · 1998
LESCOL: Notice of Compliance 2922
Issued March 6, 1998
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2922
- Date
- March 6, 1998
- Company
- Sandoz Canada Inc.Saint-Hubert, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: to slow the progression of coronary atherosclerosis in patients with coroanry heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels.
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LESCOL | Not yet assigned | — |
Medicinal ingredients
- FLUVASTATIN SODIUM 20 MG per CAP
- FLUVASTATIN SODIUM 40 MG per CAP